Stay updated on Pembrolizumab + Chemo +/- Lenvatinib in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Chemo +/- Lenvatinib in Lung Cancer Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FT8--KBZmmmUCuy537f_PJcEtviM.uncropped.jpg&w=3840&q=75)
Latest updates to the Pembrolizumab + Chemo +/- Lenvatinib in Lung Cancer Clinical Trial page
- ChecktodayNo Change Detected
- CheckyesterdayNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe website has been updated to version v2.10.0, adding 3 more interventions/treatments, 4 more study numbers, and noting that the study now has 158 locations.SummaryDifference0.3%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.0%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the version of the web page content.SummaryDifference0.0%
- Check30 days agoChange DetectedThe value of Last Update Posted (Estimated) Revision has changed from v2.9.3 to v2.9.5, indicating an update in the study record details.SummaryDifference0.0%
- Check31 days agoChange DetectedThe value 2023-10-06 2024-06-21 2023-10-04 Last Update Posted 2023-10-06 2023-09 Revision: v2.9.1 has recently changed to 2024-06-25 2024-08-30 2024-06-24 Last Update Posted (Estimated) 2024-06-25 2024-06 Revision: v2.9.3. The update represents a change in the study record dates, including the last update posted and the revision version, indicating recent modifications and updates to the study information.SummaryDifference0.5%
- Check32 days agoChange DetectedThe value 'Show more Show more Revision: v2.9.0' has been updated to 'Show less MedlinePlus Genetics related topics: Lung cancer MedlinePlus related topics: Lung Cancer Drug Information available for: Pemetrexed Pemetrexed disodium Lenvatinib Pembrolizumab FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : Randomized Interventional Model : Parallel Assignment Masking : Double ( Participant Investigator ) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib Participants receive carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily for up to 2 years. Biological : Pembrolizumab IV infusion Q3W Other Names: MK-3475 Drug : Carboplatin IV infusion Q3W Drug : Cisplatin IV infusion Q3W Drug : Pemetrexed IV infusion Q3W Drug : Lenvatinib Oral capsule once daily Other Names: MK-7902 E7080 Placebo Comparator : Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo In Parts 1 and 2: Participants receive carboplatin AUC5 or cisplatin 75 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily for up to 2 years.SummaryDifference35%
Stay in the know with updates to Pembrolizumab + Chemo +/- Lenvatinib in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Chemo +/- Lenvatinib in Lung Cancer Clinical Trial page.